Health Care • Biotechnology: Pharmaceutical Preparations
$48.64 ▼ -1.86
(-3.68%)
MKT CAP: $1.44B • VOL: 414.4K
52W L $20 52W H $72
ROARABLE / RQD
C- • 61/100
PIOTROSKI
7 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$41
MEDIAN
$54
MEAN
$55
HIGH
$66
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ANAB TAPE
ANAB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $58.85 | $55.94 | 2025-02-14 | $44.26 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $61.29 | $57.40 | 2025-02-06 | $45.72 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $55.45 | $53.50 | 2025-01-29 | $46.69 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $49.61 | — | 2025-01-17 | $47.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $42.80 | $46.21 | 2025-01-09 | $43.29 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $57.88 | $50.59 | 2024-12-18 | $42.32 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $47.18 | $49.13 | 2024-12-04 | $45.24 | -4.3% | 48% | C |